RxDoctor Payments Data

Luis Vega, MD

Family Medicine · Colon, MINPI 1659398592

Payments from drug & device makers

$419in general payments, 2019–2025

Across 30 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$96
  • AstraZeneca$74
  • Novartis$36
  • AbbVie$27
  • Boehringer Ingelheim$26
  • Shire North American Group Inc$26
  • plus $134 from 9 others

What the payments were for

  • Food & beverage$419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$419 in reported general payments places this provider in the 55th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$55,490
Medicare patients
212
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$94,025
TrulicityDulaglutide68$81,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$61,682
JardianceEmpagliflozin30$44,462
XareltoRivaroxaban38$42,954
JanuviaSitagliptin Phosphate27$30,578
EliquisApixaban20$15,257
EntrestoSacubitril/Valsartan13$14,122
Tresiba Flextouch U-200Insulin Degludec14$12,467
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$11,798
Breo ElliptaFluticasone/Vilanterol29$11,544
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$8,532
MyrbetriqMirabegron20$7,566
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$7,227
DapagliflozinDapagliflozin Propanediol11$6,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$96$94,02591 claims
Lilly USA, LLCTrulicity$13$81,61868 claims
GSKTrelegy Ellipta, Breo Ellipta$12$73,226106 claims
Boehringer IngelheimJardiance$26$44,46230 claims
Johnson & JohnsonXarelto$16$42,95438 claims
MerckJanuvia$11$30,57827 claims
NovartisEntresto$36$14,12213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Colon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →